Abstract
Von Willebrand disease is a relatively common inherited bleeding disorder. Knowledge of the various types of von Willebrand disease is important for understanding modalities necessary to diagnose and manage the disorder. Solve it!
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Castaman G. Treatment of von Willebrand disease with FVIII/VWF concentrates. Blood Transfus. 2011;9(Suppl 2):S9–13.
Coller BS. The effects of ristocetin and von Willebrand factor om platelet electrophoretic mobility. J Clin Invest. 1978;61(5):1168–75. Available from: https://pubmed.ncbi.nlm.nih.gov/307006/. Accessed 28 Feb 2022.
James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280–300.
Federici AB. Prophylaxis of bleeding episodes in patients with von Willebrand’s disease. Blood Transfus. 2008;6(Suppl 2):S26–32.
Giannini S, Cecchetti L, Mezzasoma AM, Gresele P. Diagnosis of platelet-type von Willebrand disease by flow cytometry. Haematologica. 2010;95(6):1021–4.
Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood. 2011;117(25):6777–85.
Jenkins PV, O’Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion. 2006;46(10):1836–44.
Higgins RA, Goodwin AJ. Automated assays for von Willebrand factor activity. Am J Hematol. 2019;94(4):496–503.
Pathare A, Al Omrani S, Al Hajri F, Al Obaidani N, Al Balushi B, Al Falahi K. Bleeding score in Type 1 von Willebrand disease patients using the ISTH-BAT questionnaire. Int J Lab Hematol. 2018;40(2):175–80.
Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood. 2015;125(13):2029–37.
Lavin M, O’Donnell J. New treatment approaches to von Willebrand disease. Hematology Am Soc Hematol Educ Program. 2016;2016(1):683–9.
Humate-P® Prescribing Information. CSL Behring, LLC, Kankake, IL. June 2020.
Wilate® Prescribing Information. Octapharma USA Inc., Hoboken, NJ. September 2019.
Jenkins PV, Rawley O, Smith OP, O’Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol. 2012;157:653–63.
VONVENDI® Prescribing Information. Baxalta US, Inc., Lexington, MA. February 2019.
Further Reading
Federici AB. Prophylaxis of bleeding episodes in patients with von Willebrand’s disease. Blood Transfus. 2008;6(Suppl 2):S26–32.
James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280–300.
Sadler JE. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Am Soc Hematol. 2009;2009:106–12. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20008188. Accessed 28 Feb 2022.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Friedman, M.T., West, K.A., Bizargity, P., Annen, K., Gur, H.D., Hilbert, T. (2023). It’s So “Vonderful”. In: Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy. Springer, Cham. https://doi.org/10.1007/978-3-031-14638-1_56
Download citation
DOI: https://doi.org/10.1007/978-3-031-14638-1_56
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-14637-4
Online ISBN: 978-3-031-14638-1
eBook Packages: MedicineMedicine (R0)